Clinical trial
Amifostine in Treating Patients With Ovarian Epithelial Cancer Who Are Receiving…
NCT00004166 · Northwestern University, Other · Completed
Key facts
| NCT number | NCT00004166 |
|---|---|
| Title | Amifostine in Treating Patients With Ovarian Epithelial Cancer Who Are Receiving Chemotherapy |
| Official title | Amifostine as a Toxicity Protectant in Ovarian Cancer in Chemotherapy Treated Patients: A Pilot Phase III Randomized Controlled Trial |
| Lead sponsor | Northwestern University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Ovarian Cancer, Quality of Life |
| Intervention type | Drug, Procedure |
| Interventions | amifostine trihydrate, quality-of-life assessment |
| Start date | Oct 1, 1999 |
| Primary completion | Jan 1, 2003 |
| Completion | Jan 1, 2003 |
| First posted | Apr 12, 2004 |
| Last update posted | Jun 6, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: